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Background: The effectiveness of personal health records (PHRs) in diabetes management has already been verified in several
clinical trials; however, evidence of their effectiveness in real-world scenarios is also necessary. To provide solid real-world
evidence, an analysis that is more accurate than the analyses solely based on patient-generated health data should be conducted.
Objective: This study aimed to conduct a more accurate analysis of the effectiveness of using PHRs within electronic medical
records (EMRs). The results of this study will provide precise real-world evidence of PHRs as a feasible diabetes management
tool.
Methods: We collected log data of the sugar function in the My Chart in My Hand version 2.0 (MCMH 2.0) app from Asan
Medical Center (AMC), Seoul, Republic of Korea, between December 2015 and April 2018. The EMR data of MCMH 2.0 users
from AMC were collected and integrated with the PHR data. We classified users according to whether they were continuous app
users. We analyzed and compared their characteristics, patterns of hemoglobin A1c (HbA1c) levels, and the proportion of successful
HbA1c control. The following confounders were adjusted for HbA1c pattern analysis and HbA1c regulation proportion comparison:
age, sex, first HbA1c measurement, diabetes complications severity index score, sugar function data generation weeks, HbA1c
measurement weeks before MCMH 2.0 start, and generated sugar function data count.
Results: The total number of MCMH 2.0 users was 64,932, with 7453 users having appropriate PHRs and diabetes criteria. The
number of continuous and noncontinuous users was 133 and 7320, respectively. Compared with noncontinuous users, continuous
users were younger (P<.001) and had a higher male proportion (P<.001). Furthermore, continuous users had more frequent HbA1c
measurements (P=.007), shorter HbA1c measurement days (P=.04), and a shorter period between the first HbA1c measurement
and MCMH 2.0 start (P<.001). Diabetes severity–related factors were not statistically significantly different between the two
groups. Continuous users had a higher decrease in HbA1c (P=.02) and a higher proportion of regulation of HbA1c levels to the
target level (P=.01). After adjusting the confounders, continuous users had more decline in HbA1c levels than noncontinuous
users (P=.047). Of the users who had a first HbA1c measurement higher than 6.5% (111 continuous users and 5716 noncontinuous
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users), continuous users had better regulation of HbA1c levels with regard to the target level, 6.5%, which was statistically
significant (P=.04).
Conclusions: By integrating and analyzing patient- and clinically generated data, we demonstrated that the continuous use of
PHRs improved diabetes management outcomes. In addition, the HbA1c reduction pattern was prominent in the PHR continuous
user group. Although the continued use of PHRs has proven to be effective in managing diabetes, further evaluation of its
effectiveness for various diseases and a study on PHR adherence are also required.
(J Med Internet Res 2020;22(6):e15372) doi: 10.2196/15372
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Introduction
Background
Diabetes mellitus is a global issue, and its contribution to
numerous complications and increased mortality is well known.
Moreover, diabetes prevalence is constantly growing, a trend
that might continue until 2030 or longer [1,2]. According to the
American Diabetes Association (ADA), diabetes care is mainly
based on insulin delivery [3]. According to the Korean Diabetes
Association (KDA), the target value of hemoglobin A1c (HbA1c)
is recommended to be 6.5% for patients with type 2 diabetes,
and antihyperglycemic therapy is mainly considered in Korea.
Metformin is considered to be the first-line therapy. However,
these traditional drug therapies result in inevitable hypoglycemic
events and body weight change. An unachieved glycemic target
can only be solved by increasing drugs in mono, dual, or triple
therapy [4]. Traditional methods are expensive, and this is
becoming a national health care problem [5,6]. To overcome
several limitations of traditional diabetes management, mobile
health (mHealth) technology and personal health record (PHR)
implementation have been suggested as innovative solutions.
In the diabetes management market, new treatments with new
devices and apps are being introduced. Most functions of
diabetes apps focus on maintaining a blood glucose diary. Some
are also connected with blood glucose sensors and treatment
devices. Among diabetes apps, OneTouch Reveal had the best
validation [7]. This app is wirelessly connected to the OneTouch
Verio Flex meter, making users self-monitor their blood glucose.
Blood glucose data are delivered to health care professionals,
and users receive text message feedback [8]. Technologies using
automatic alarm systems have also been introduced. The
Dexcom G6 Continuous Glucose Monitoring system effectively
reduced hyperglycemia and also hypoglycemic events with the
Urgent Low Soon automatic alert system [9]. Monitoring insulin
delivery became possible with internet-based connections.
NovoPen 6 and NovoPen Echo Plus are called smart insulin
pens, which can monitor the insulin injection amount and
provide both health providers and patients treatment accuracy
[10,11].
Previous studies have shown the health improvement of PHR
users, thus suggesting that a digital health care system is feasible
for improving health behavior and chronic conditions. According
to a systematic review, users experienced a positive effect on
their health-related behavior and clinical results when using
health apps on their mobile devices [12]. Another systematic
review in South Korea showed that mHealth interventions were
effective in improving self-management behaviors, biomarkers,
or patient-reported outcome measures [13]. However, the
positive effect of mHealth and PHR interventions is not always
ensured.
In diabetes care, PHR and mHealth interventions are expected
to be effective treatments. WellDoc, a remote blood glucose
monitoring system, was effective in lowering HbA1c levels,
thereby improving clinical, behavioral, and diabetes knowledge
outcomes [14]. A phone-based treatment and behavioral
coaching intervention also improved HbA1c levels [15]. A
similar improvement in HbA1c control for type 2 diabetes was
seen with another mobile-based intervention [16]. The addition
of a tailored mobile coaching system for patients with diabetes
showed reduced HbA1c levels and improved diabetes
self-management; the results were reproducible and durable
[17].
Along with the expectations of the clinical implications of PHRs,
some concerns and slightly controversial results have been
reported. Despite its advantages, studies have reported the
barriers in PHR implementation. Patients are concerned about
the security of their health information. Health care providers
are concerned about patients altering their own PHR
information. Other issues are that there is no practical difference
in health outcomes, the use of stand-alone PHRs with electronic
medical records (EMRs) and electronic health records, and a
low health care literacy rate, which can diminish the benefits
of PHRs [18]. Moreover, the barriers associated with patients’
age, sex, socioeconomic status, education level, internet and
computer access, and health have been reviewed [19].
Contrasting results of the relation between PHR use and diabetes
management have been reported. A study using a regression
model claimed that there was no association between the
increasing number of days of PHR use and better diabetes
quality measure profiles [20].
Objectives
In this study, we used a 4-year mobile PHR (mPHR) log and
users’ EMR data to analyze the effects of diabetes management
on the continuous use of the PHR system distributed by a tertiary
hospital in South Korea. A study with the earlier version of the
mPHR app was conducted to verify characteristics of continuous
users [21], and patient-generated health data (PGHD) of
continuous users had a higher proportion of a chronic disease
diagnosis, such as diabetes, than noncontinuous users [22]. With
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the new version, we will verify its effect in glycemic control
on patients with diabetes. To the best of our knowledge, this is
the first study to verify the effectiveness of disease management
by integrating a long-term mPHR log and EMR data.
Methods
Data and Mobile Personal Health Record Description
We collected log data from an mPHR app called My Chart in
My Hand (MCMH) and their EMR data at the Asan Medical
Center (AMC), which is the largest general hospital in South
Korea. Launched in January 2011, MCMH is the first mPHR
in South Korea; it enables patients to view and manage their
own health records [21]. We used the MCMH version 1.0 log
to identify patterns of continuous generation of PGHD in
specific populations [22]. This study performed a diabetes
management analysis using the MCMH version 2.0 log and
EMR data. For patients with diabetes, MCMH version 2.0
provides sugar, diabetes calendar, insulintreatment, food intake,
and exercise input functions. Among these functions, we only
used the log data of the sugar and diabetes calendar function;
the remaining functions had very few records. The items in
Figure 1 show the details of the sugar function. Users enter the
date, time, situation, and result of their blood glucose
measurement in these PGHD functions.
We also gathered demographic and medical record information
of patients, such as age, sex, residence, and health information,
including hospital visits, HbA1c level, diagnosis, and medication
data, using our clinical research data warehouse.
Figure 1. Screenshots of My Chart in My Hand version 2.0. Inputting data in the sugar function follows from the home page to Enter Blood Glucose.
Study Design
MCMH version 2.0 replaced MCMH version 1.0 on December
31, 2015, but some patients had already created their accounts
in December 2015 before the replacement. For each user, the
records generated in MCMH version 2.0 functions were
analyzed, but only records generated after account creation were
used.
The user log of the sugar function contained user access ID and
time stamps of data input. We gathered the HbA1c measurement
results of MCMH version 2.0 users from January 2014 to
November 2018.
For user selection, we used the criteria of diabetes for diagnosis.
First, the criterion of Glasheen et al [23] was adopted: a user
should have one or more International Classification of Diseases
10th Revision (ICD-10) diabetes codes in the diagnosis record,
which are E08, E09, E10, E11, and E13. Second, the HbA1c
cutoff value of 6.5% for diagnosing diabetes was used [24]. For
the complication classification and diabetes complications
severity index (DCSI) scoring, the selected complication fields
from the diagnosis record were retinopathy, nephropathy,
neuropathy, cerebrovascular, cardiovascular, peripheral vascular
disease, and metabolic complications. DCSI scoring used the
criteria of the study by Glasheen et al [23]. However, urine
laboratory data were not included in DCSI scoring because of
its unavailability. Above all, we classified all diseases according
to ICD-10.
The criterion for whether a user was a continuous user was
adopted from the PGHD pattern analysis study of MCMH
version 1.0: a user entering data in the sugar function at least
once per week and doing so for at least four weeks (28 days)
[22].
We analyzed the pattern of HbA1c levels with the trend line
slope of HbA1c levels. The fluctuation of HbA1c levels was
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compared with the r-squared value of the trend line and the
standard deviation of the patient’s HbA1c level.
In this study, the trend line slope considerably depended on the
measurement days between the first and last HbA1c
measurement. Therefore, we created a patient filter called
appropriate HbA1c measurement. This criterion excluded
patients with short periods between measures because a short
period will lead to an exaggeratedly steep slope, which is
inappropriate for the analysis. The criterion for an appropriate
HbA1c measurement is patients should have at least two HbA1c
measurements and the period between the first and last HbA1c
measurement should be over 100 days. To normalize the effect
of measurement days between the first and last HbA1c
measurement, we defined a variable called decline. Decline is
defined as a trend line slope times the period (in days) divided
by 100. This normalization is represented in the equation in
Multimedia Appendix 1.
This study was approved by the Institutional Review Board
(IRB) of the AMC (IRB number: 2018-0321). The need for
informed consent was waived by the ethics committee because
this study utilized routinely collected log data that were
anonymously managed at all stages, including during data
cleaning and statistical analyses.
Study Participants
Figure 2 shows the patient selection flow in this study. Among
64,932 users who downloaded and created an MCMH version
2.0 account, we first excluded 51,433 users with inappropriate
HbA1c measurements. We considered 13,499 users with the
appropriate HbA1c measurements, excluded 6046 users without
diabetes, and selected 7453 users with diabetes.
Figure 2. Patient inclusion and exclusion criteria (white boxes) and flow through the study. The gray box shows user hemoglobin A1c (HbA1c) analyses.
Criteria for appropriate HbA1c measurement: two or more HbA1c measurements, duration of the first and last measurement over 100 days, and creating
My Chart in My Hand version 2.0 account during HbA1c measurement. Criteria for diabetes diagnosis: having International Classification of Diseases
10th Revision code E08, E09, E10, E11, or E13 or first HbA1c measurement ≥6.5%. Criteria for continuous use of sugar function: patient-generated
health data entered in the sugar function at least once per week and used for at least 28 days. aHbA1c: hemoglobin A1c; 
bMCMH: My Chart in My Hand.
Data Analysis
We first compared the general characteristics of continuous
(n=133) and noncontinuous users (n=7320). The following
characteristics were compared: age, gender proportion, sugar
and diabetes calendar function use pattern, HbA1c measurement
pattern, HbA1c value, DCSI score, and complication proportion.
A Student t test was conducted for the comparison of age, the
number of HbA1c measurements, measurement days, and
measurement days before MCMH version 2.0 start. A Wilcoxon
rank-sum test was used for individual sugar and diabetes
calendar function data generation, HbA1c measure frequency,
first HbA1c measurement, and DCSI score comparison. The
median test was used for the individual sugar and
diabetescalendar function data generation comparison. The Z
test was conducted for sugar and diabetes function generation
user proportion, first HbA1c measurement over 6.5% proportion,
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and complications proportion comparisons. For gender
proportion comparison and DCSI score distribution, a chi-square
test was used.
Next, comparative analyses of HbA1cdecline, r-squared value,
and standard deviation between continuous and noncontinuous
users were performed. We used the Shapiro-Wilk test and
D’Agostino K-squared test to determine if these data followed
a normal distribution. HbA1cdecline, r-squared value, and
standard deviation were compared using the Wilcoxon rank-sum
test. For confounder adjustment, we used an analysis of
covariance (ANCOVA) with some variables: continuous use,
age, sex, first HbA1c measurement, DCSI, sugar function data
generation weeks, HbA1c measurement in weeks before MCMH
version 2.0 start, and sugar function data generation count.
Finally, the Z test was conducted for comparing the proportions
of 4 groups between continuous and noncontinuous users. The
4 groups were divided by whether the first HbA1c measurement
was higher or lower than 6.5% and whether the last HbA1c
measurement was higher or lower than 6.5%. For confounder
adjustment, multivariable logistic regression was used for users
with the first HbA1c measurement over 6.5%. The same
variables, as used in ANCOVA, were used for logistic




Within 29 months of operation of MCMH version 2.0, 64,932
users created an account and logged in at least once. Among
these users, 7453 users were selected on the basis of the
inclusion criteria of this study. Approximately 1.78% (133/7453)
of these users were continuous users, and 98.22% (7320/7453)
were noncontinuous users. Continuous and noncontinuous users
had no statistically significant difference in the number of HbA1c
measurements and the period between the first and last HbA1c
measurements.
Table 1 summarizes the results of a basic characteristic analysis
between continuous and noncontinuous users. In Table 1,
measure frequency refers to the number of measurements per
day, measurement days refers to days between the first and last
HbA1c measurement, and measurement days before MCMH
version 2.0 start refers to days between the first HbA1c
measurement and MCMH version 2.0 account generation period.
Compared with noncontinuous users, continuous users were
younger (mean 53.59, SD 9.89 years vs mean 57.58, SD 11.95
years, respectively) and had a higher male proportion (110/133,
82.7% vs 4859/7320, 66.38%, respectively), which was
statistically significant (both P<.001). The number of HbA1c
measurements was not significantly different. The frequency
and period between the first and last measurements exhibited
a significant difference between continuous and noncontinuous
users (P=.007 and P=.04, respectively). The proportion of
patients with the first HbA1c measurement below 6.5% had no
significant difference (P=.14), but continuous users had a higher
first HbA1c measurement, and this was statistically significant
(P=.01). Furthermore, among continuous users, there were a
higher proportion of users who generated data in the sugar
function and diabetes calendar function (both P<.001).
Continuous users also entered more sugar and diabetes calendar
data (both P<.001). The DCSI score had no significant
difference (P=.99). The proportion of complications, defined
by the DCSI criteria, also showed no significant difference
between continuous and noncontinuous users. Although the
difference was statistically insignificant, retinopathy and
cardiovascular complications had a proportional difference.
The DCSI score proportion of continuous and noncontinuous
users had no significant difference in the chi-square test. This
can be found in Multimedia Appendix 2. Among the 14 DCSI
scores, those with zero proportion in both patient groups (scores
10, 12, and 13) were excluded in the analysis using the
chi-square test, because calculation with the chi-square test is
only possible when each score does not have zero proportion
in any group.
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Table 1. General characteristics of continuous and noncontinuous users.
P valueaTotal (N=7453)UsersVariables
Noncontinuous (n=7320)Continuous (n=133)
<.00157.51 (11.92)57.58 (11.95)53.59 (9.89)Age (years), mean (SD)
<.001Sex, n (%)
4969 (66.67)4859 (66.37)110 (82.7)Male
2484 (33.33)2461 (33.62)23 (17.3)Female
Sugar function
<.001422 (5.66)289 (3.95)133 (100.0)Data generated by users, n (%)
—b23,695134522,350Total data generated, n
<.001Individually generated data
3.2 (35.1)0.2 (1.8)168.0 (204.0)Mean (SD)
0 (0-0)0 (0-0)97 (43-186)Median (IQR)
Diabetes calendar function
<.001430 (5.77)297 (4.06)133 (100.0)Data generated by users, n (%)
—17,860145316,407Total data generated, n
<.001Individually generated data
2.4 (25.4)0.2 (4.0)123.4 (143.3)Mean (SD)
0 (0-0)0 (0-0)67 (35-145)Median (IQR)
HbA1c
c , mean (SD)
.3811.92 (6.82)11.90 (6.82)12.44 (6.90)Number of measurements
.0070.009 (0.005)0.009 (0.005)0.011 (0.010)Measure frequency
.041335 (446)1336 (445)1254 (461)Measurement days
<.001710 (377)712 (377)546 (348)Measurement days before MCMHd version 2.0 start
.145827 (78.18)5716 (78.09)111 (83.4)First HbA1c measurement ≥6.5%, n (%)
.017.51 (1.62)7.51 (1.62)7.86 (1.78)First HbA1c measurement, mean (SD)
.991.15 (1.64)1.15 (1.64)1.17 (1.65)DCSIe, mean (SD)
Complications, n (%)
.461547 (20.75)1516 (20.71)31 (23.3)Retinopathy or ophthalmic
.80778 (10.44)765 (10.45)13 (9.8)Nephropathy
>.991290 (17.31)1267 (17.31)23 (17.3)Neuropathy
.48970 (13.01)950 (13.00)20 (15.0)Cerebrovascular
.051382 (18.54)1366 (18.7)16 (12.0)Cardiovascular
.9460 (0.81)59 (0.8)1 (0.8)Peripheral vascular disease
.6938 (0.51)37 (0.5)1 (0.8)Metabolic complications
aChi-square test or Z test (for categorical variables); Student t test or Wilcoxon rank-sum test (for continuous variables).
bStatistical comparison was not conducted in total generated data of sugar and diabetes calendar function.
cHbA1c: hemoglobin A1c.
dMCMH: My Chart in My Hand.
eDCSI: diabetes complications severity index.
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Hemoglobin A1c Pattern Analysis According to
Continuous Use
Figure 3 shows the trend of the HbA1c pattern for continuous
and noncontinuous users. The HbA1cdecline of continuous and
noncontinuous users was also compared. The HbA1cdecline
(mean −0.00533, SD 0.0144) in continuous users was
significantly steeper than that of noncontinuous users (mean
−0.00278, SD 0.0137; P=.02). The SD of continuous users
(mean 0.832, SD 0.574) was significantly higher than that of
noncontinuous users (mean 0.719, SD 0.541; P=.005). However,
the r-squared value had no statistically significant difference
between continuous and noncontinuous users (P=.40).
When adjusting confounders that can contribute to the decline,
continuous use had a statistically significant effect (P=.047) on
making decline steeper, as seen in Table 2. In addition, age,
first HbA1c measurement, DCSI, weeks of sugar function data
generation, and HbA1c measurement in weeks before MCMH
version 2.0 start showed statistically significant effects (P=.004;
P<.001; P=.01; P=.003; P<.001, respectively).
Figure 3. Hemoglobin A1c (HbA1c) patterns (decline, r-squared value, and SD) of continuous and noncontinuous users. The x-axis is the percentage
of days past from the first HbA1c measurement compared with the period between the first and last HbA1c measurements. The dashed lines are the
HbA1c decline of each patient. The slope and y-axis intercept of the continuous lines indicates the mean of slope and y-axis of patients, respectively.
Table 2. Results of adjusting confounders with the analysis of covariance in decline comparison.







.0038.68Sugar function data generation (weeks)
<.001154.25HbA1c measurement weeks before MCMH version 2.0 start
.860.03Generated sugar function data count
aHbA1c: hemoglobin A1c.
bDCSI: diabetes complications severity index.
Comparison of Hemoglobin A1c Regulation With
Target Level in Continuous Use
Table 3 lists the proportion with regard to HbA1c patterns. The
proportion of users with the first HbA1c measurement higher
than 6.5% and the last HbA1c measurement lower than 6.5%
had a statistical difference (P=.01). Among users with the first
HbA1c measurement lower than 6.5%, the proportion of patients
with the last HbA1c measurement lower than 6.5% and the last
HbA1c measurement higher than 6.5% had no significant
difference (P=.34 and P=.29, respectively). No significant
difference was found between proportions of patients with the
first HbA1c measurement of 6.5% or higher and the last HbA1c
measurement higher than 6.5% (P=.41).
Similar to the decline analysis, the result of confounder
adjustment by logistic regression for users with a high first
HbA1c measurement is summarized in Table 4. The continuous
use of MCMH version 2.0 had a statistically significant effect
in helping users move from an HbA1c measurement above 6.5%
to an HbA1c measurement below 6.5% (P=.04). In addition,
age, first HbA1c measurement, and HbA1c measurement in weeks
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before MCMH version 2.0 start showed statistically significant effects (all: P<.001).






.341040 (14.21)15 (11.3)<6.5%, n (%)
.29564 (7.70)7 (5.3)≥6.5%, n (%)
First measurement ≥ 6.5%
Last measurement
.01564 (7.70)38 (28.6)<6.5%, n (%)
.414278 (58.44)73 (54.9)≥6.5%, n (%)
aHbA1c: hemoglobin A1c.










.23−0.004Sugar function data generation (weeks)
<.001−0.008HbA1c measurement in weeks before MCMH
c version 2.0 use start
.52−0.001Generated sugar function data count
aHbA1c: hemoglobin A1c.
bDCSI: diabetes complications severity index.
cMCMH: My Chart in My Hand.
Discussion
Principal Findings
For the following reasons, this study supports the use of mPHRs
as an effective platform for diabetes management by integrating
patient-generated health and clinical data from PHRs and EMRs,
respectively. First, analyzing the characteristics of continuous
users of MCMH version 2.0, male patients with a high HbA1c
level seemed to use MCMH version 2.0 more continuously.
Second, the continuous use of PHRs resulted in a higher
decrease of HbA1c levels and enhanced the regulation of high
HbA1c levels of patients to the target range. Therefore, male
users with high HbA1c levels had a higher decrease in HbA1c
levels and improved HbA1c regulation to the target level. By
analyzing the characteristics of continuous users and their HbA1c
patterns, we also suggest the use of mPHR as a diabetes care
support tool enabling personalized management.
This study is unique when compared with previous studies on
the basis of the following characteristics. First, we suggested
the health improvement effect of mPHRs on the basis of the
integration of PHRs and EMRs. In this study, we expected two
benefits of integrating PHRs and EMRs. One is suggesting a
different methodology for real-world data analysis and
presenting additional real-world evidence, which supports
previous studies. Another is ensuring a high-quality data analysis
is conducted. There are many previous studies implying the
advantages of PHRs and PGHD with positive conclusions of
the use of mPHRs [14-17]. The results of these studies were
collected on the basis of clinical trials such as nonblinded,
open-label randomized controlled trials (RCTs) and
cluster-randomized trial designs. As a real-world data analysis
covers bias limitations in RCTs and can handle unknown factors
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of PHRs, the results of a real-world data analysis provide strong
and necessary support to previous RCTs [25]. Moreover, the
integration of EMRs gave high-quality HbA1c data and diagnosis
data, which made the analysis more precise.
Second, previous studies mainly discussed about the decrease
in HbA1c levels as an advantage of using PHRs. However, as
the main goal of glycemic control is regulating a patient’s HbA1c
level to the recommended range, we compared both HbA1c
decrease and proportions of patients who initially had a high
HbA1c level but their HbA1c level decreased to a low value.
According to the 2015 and 2019 diabetes management
guidelines from the KDA, the recommended target HbA1c level
is 6.5% in patients with type 2 diabetes, and this differs from
the guideline by the ADA [4,26,27]. As this study was conducted
in AMC, South Korea, we used the guidelines from KDA and
defined the cutoff value of the HbA1c level as 6.5%. Recent
studies recommend that patients with severe diabetes mellitus
should be controlled to lower than 7%, depending on the severity
and complications of diabetes [28-30]. Moreover, a stable
decrease in blood glucose levels is also an important task in
glycemic control. We also focused on the r-squared value of
the trend line and SD as an indicator of stabilized HbA1c
decrease, but we could not achieve any outstanding results.
Overall User Characteristics
Analyzing users who had access to MCMH version 1.0 indicated
that these users visited hospitals more with chronic diseases
[21]. Continuous users were younger than noncontinuous users
(P<.001), and there was a significant difference in sex
proportion; the continuous user group had a higher male ratio
(P<.001). In previous research, groups that used a PHR system
had young users and a high proportion of males or generated
more PGHD, especially those related to diabetes [21,22]. This
is because male users aged between 51 and 70 years tend to
adopt the PHR system [31]. In addition, in this study, the HbA1c
level in continuous users was measured for a shorter period
(P=.04) and more frequently (P=.007) than noncontinuous users.
However, the number of HbA1c measurements had no significant
difference between continuous and noncontinuous user groups.
In South Korea, the social health insurance program was
introduced with the 1977 National Health Insurance Act. This
program was thereafter progressively rolled out to the general
public, and it finally achieved universal coverage in 1989.
According to the National Health Insurance Act, the criteria for
the method, procedure, scope, and upper limit of health care
shall be prescribed by the Ministry of Health and Welfare [17].
National insurance only supports up to 6 HbA1c tests per year,
in accordance with the National Health Insurance Act. First, we
considered the number of HbA1c measurements as another
indicator of diabetes severity. This is because well-controlled
patients typically undergo HbA1c tests twice a year, whereas
poorly controlled individuals undergo testing 4 times a year
[32]. However, the number of measurements seems to be similar
because of the policy in South Korea. Although continuous
users had shorter periods (approximately 80 days) between the
first and last measurements, this group took HbA1c tests more
frequently. This may be because of the increase in hospital
visits, along with more satisfaction and loyalty to the hospital
[33]. To compare diabetes severity, the proportion of patients
with an HbA1c level of 6.5% or above, a first HbA1c level
measurement, and a DCSI score distribution were compared
between continuous and noncontinuous groups. The two groups
had no significant difference in the proportion of high HbA1c
levels and DCSI distribution; however, continuous users had a
higher HbA1c level (P=.01). Retinopathy patients tended to use
MCMH version 2.0 more continuously, but the complication
proportion also had an insignificant difference between the two
groups. Except for the first HbA1c level measurement, most
diabetic-related baseline characteristics appeared to have no
significant difference, and the first HbA1c measurement can be
adjusted as confounders in an additional analysis. By using PHR
and EMR integration, the general characteristics and severity
of diabetes were compared.
As the period of HbA1c measurement before MCMH version
2.0 use was shorter in the continuous group (P<.001), continuous
users seemed to have an earlier MCMH version 2.0 start
compared with noncontinuous users. In addition, continuous
users tended to use the sugar and diabetes calendar functions
more and generate more data. This was because continuous
users tended to use MCMH version 2.0 functions with fewer
burdens.
Verifying the Effect of Personal Health Record Use in
Hemoglobin A1c Control
The main advantage of PHRs and PGHD is health improvement,
especially in diabetes. Among the types of diabetes management,
determining the change in HbA1c levels was the most effective
method to verify the effectiveness of PHRs in the real world.
The results of this study indicate that continuous users had a
larger decline; a greater increase in HbA1c levels was observed
in users who continuously used the diabetes management–related
sugar function in MCMH version 2.0. As decline is the result
of the trend line slope normalized to 100 days, the value itself
also refers to the change in the HbA1c level. For example, HbA1c
was 6.9% on January 1, 2014, and HbA1c was 6.4% on October
19, 2018, in one particular continuous user; therefore, the decline
value was −0.0044, which means that this patient’s change in
HbA1c level was approximately −0.44% (100 times the value
of decline). Thus, the decrease in HbA1c levels in continuous
users was approximately 1.9 times that in noncontinuous users.
The result of ANCOVA shows that along with continuous use,
other factors were also important: age, first HbA1c measurement,
DCSI, duration of using the sugar function, and HbA1c
measurement period before using MCMH version 2.0. Glycemic
control is important for reducing both microvascular risk and
emergent risk for myocardial infarction and death [34]. This
indicates that the group that continuously used PHRs had health
improvement with a decreasing trend of HbA1c levels.
In glycemic control, it is important to reduce not only blood
glucose levels but also hypoglycemic events [35]. Traditional
diabetes care includes insulin delivery using syringes, pens, or
pumps [3]. Although hypoglycemic side effects can occur with
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multiple daily injections and continuous subcutaneous insulin
injection, the invasive characteristic of such forms of care is an
inevitable disadvantage [36-39]. In this study, we tried to
minimize the risk of hypoglycemic events in PHR-implemented
diabetes management by using stability indicators, r-squared
value and SD. However, stability was not ensured. In fact, a
previous study showed increased glucose stability with the use
of an internet-based glucose monitoring system [40]. This
indicates that patients can improve hyperglycemia and
hypoglycemia management by using PHRs with a blood glucose
meter through continuous glucose monitoring diabetic care.
The goal of decreasing the HbA1c level is to prevent the
occurrence and aggravation of diabetic complications. Although
the criterion for HbA1c in a diagnostic test for diabetes has been
recommended by the American Association of Clinical
Endocrinologists and ADA, it is an “acceptable complementary
diagnostic test for diabetes in Korean patients” [28,41]. Among
the many glycemic controls, the tight regulation of HbA1c levels
is essential for health improvement and for lowering
complication risks such as diabetic retinopathy [42]. In addition,
the tight glycemic control of HbA1c levels to 7.0% induces a
lower risk of fracture in elderly patients with diabetes [43].
When comparing the ratio of patients with HbA1c levels above
and below 6.5% before and after the use of MCMH version 2.0,
the group that continuously used MCMH version 2.0 had a
higher proportion of regulated patients; initially, the first HbA1c
level measurement was over 6.5%, and then it reduced to lower
than 6.5%. In addition, among users with the first HbA1c level
measurement over 6.5%, the logistic regression results showed
that regulation was associated not only with continuous use but
also with age, first HbA1c level measurement, and how fast
MCMH version 2.0 was adapted. The data generation amount
was thought to be important too, but it was statistically
insignificant. Therefore, we can claim that the improvement of
HbA1c levels by PHR use can eventually affect diabetes
management by controlling HbA1c levels to 6.5% in practice.
Limitations of This Research
The main limitation of this study is the concern of general biases
in real-world studies: selection bias, information bias, recall
bias, and detection bias [44]. As this study mainly focused on
analyzing real-world data, strict criteria and inevitable exclusion
are necessary, leading to concerns in selection bias and detection
bias. However, the criteria for the comparison group were the
same, and despite including and excluding many patient criteria
and comparing with the MCMH 1.0 user analysis, the study
scale is almost similar [22]. The size of the continuous user
groups is sometimes larger than that used in other RCT studies
and had little baseline differences in diabetic severity [17]. As
MCMH version 2.0 data are PGHD, continuous use can only
be analyzed by its log data, which does not represent adherence
to the app and can lead to information bias. On the contrary,
we note that information bias that can occur in HbA1c level
scaling can be controlled with the integration of EMRs. This
integration helped in reducing recall bias in diabetes and
complication diagnosis.
Time scale is also another limitation. In RCTs, the HbA1c
measurement point, the app account creation point, and app use
frequency can be controlled and optimized for convenient data
analysis. However, in real-world data, patients have diverse
points of HbA1c measurement and MCMH version 2.0 starting
points. Even though there were limitations with regard to
missing data, inappropriate data, and ambiguous time scale
standards, we used patient selection criteria to choose patients
who can be analyzed and used the decline factor to monitor the
HbA1c level for minimizing the effect of irregular time points.
The decline factor is a variable that has been coined for the
purpose of this study and has an uncertain clinical rationale.
However, as the decline variable also implies a decrease in
HbA1c levels, and the decreasing trend is being maintained, the
quantitative comparison of decline between groups is
meaningful. In diabetes care, lowering HbA1c levels to the target
level and maintaining the decreased HbA1c level is the primary
goal. Thus, the decline is a reasonable variable for analysis in
studies with data having unspecific HbA1c measurement points.
An additional limitation is that AMC is a territorial hospital,
and almost all the study patients are residing in South Korea.
The small size of the study population and short duration are
other limitations. The low frequency of PHR data generation
and short-term MCMH version 2.0 operation is not an ideal
database for analyzing chronic diseases such as diabetes. A
larger study size and longer study duration will provide stronger
real-world evidence of the clinical meaning of PHRs.
On the basis of the proportion of continuous and noncontinuous
users, further research for encouraging patients to use PHRs
more continuously is essential. In this study, continuous users
had better diabetes management outcomes than noncontinuous
users. However, continuous users were only 1.78% (133/7453)
of the study population and were only 0.20% (133/64,932) of
users who started using MCMH version 2.0. Thus, studies for
maintaining active PGHD-generating users and turning
noncontinuous users into continuous users are necessary.
Finding out whether giving health-related advice on the basis
of MCMH version 2.0 encourages patients to use a PHR app
for changing app use patterns needs to be studied to prevent
usability issues [45]. Furthermore, for personalized PHR advice,
if larger and better quality of data is provided, the glycemic
control outcome analysis by treatment is important. Further
studies in diverse territories and a deeper analysis of MCMH
version 2.0 should be performed to prove the effectiveness of
PHRs as a diabetes management tool in decreasing HbA1c levels.
Conclusions
By integrating and analyzing patient- and clinically generated
data, the continuous use of PHRs improves diabetes management
outcomes. A greater decrease in HbA1c levels was observed in
continuous users, and HbA1c levels were regulated to the target
level in continuous users compared with noncontinuous users.
Previous clinical trials and the results of this study proved that
PHRs are effective in managing diabetes. However, further
evaluation of the effectiveness of PHRs in various diseases and
studies for adherence to PHRs are needed. A larger study
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population and longer duration will be necessary for the accurate analysis of the clinical rationale of PHRs on chronic diseases.
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